AIM-listed Sareum has announced positive Phase 1 trial results for its lead autoimmune candidate, SDC-1801, and successfully ...

Outstanding measure of efficacy relative to high-risk cancers with limited treatment optionsCHICAGO, (GLOBE NEWSWIRE) -- MAIA ...

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

Transgene and BioInvent are co-developing BT-001, an oncolytic virus developed using Transgene’s Invir.IO® platform armed to express GM-CSF and BioInvent’s full-length anti-CTLA-4 monoclonal antibody, ...